Tango Therapeutics (TNGX) Receives Price Target Boost from Guggenheim, Maintains Buy Rating

Guggenheim has raised Tango Therapeutics' (TNGX) price target from $12.00 to $18.00, a 50% increase, while maintaining a "Buy" rating. This is the latest in a series of positive analyst evaluations for the biotechnology company, which is focused on developing precision oncology therapies. The average target price for TNGX is $14.38, with an upside of 15.42% from the current price.